DaVita (DVA)
(Delayed Data from NYSE)
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 7:48 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 7:48 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
Zacks News
The 3 Widest Competitive Moats on Wall Street
by Andrew Rocco
Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.
Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.
Alcon (ALC) Expands Optical Care Line With Latest Launch
by Zacks Equity Research
Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark
by Zacks Equity Research
Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Thermo Fisher's (TMO) Strong End Markets and New Buyouts Aid
by Zacks Equity Research
Thermo Fisher (TMO) is registering strong growth in the electron microscopy and chromatography and mass spectrometry businesses in the academic and government end market.
Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod
by Zacks Equity Research
Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.
Are Investors Undervaluing Addus HomeCare (ADUS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.
ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
enVVeno (NVNO) Plans to Expedite enVVe Development for CVI
by Zacks Equity Research
enVVeno (NVNO) notes that its capital position is now strong enough to begin the enVVe pivotal study.
Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity
by Zacks Equity Research
Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.
Three Reasons to Add PacBio (PACB) Stock to Your Portfolio
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats
by Zacks Equity Research
OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.
Quest Diagnostics (DGX) to Boost Lab Services With New Pact
by Zacks Equity Research
Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.
Here's Why You Should Buy Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.
LabCorp (LH) to Expand Diagnostics Services With New Deal
by Zacks Equity Research
LabCorp's (LH) recent deal will bring together critical expertise, experience and technology from both organizations to improve the delivery of high-quality patient care.
Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery
by Zacks Equity Research
Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?